EGFR and glioblastoma: 5,38 This enhanced activation seems not solely driven by increased ligand binding of low-affinity ligands in EGFR-mutated variants.39 Our retrospective analysis of data from the Intellance-2 trial, along with our previous study,5 demonstrates that both high EGFR ligand expression and EGFR SNVs are significantly associated with improved patient responses to depatux-m combined with TMZ in EGFR-amplified recurrent GBM.